Physician profile
Anna Danielle Cramer
NPI 1124507785
$14,274.09
in general payments reported to CMS, 2019-2025
19 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,769 · 2022: $2,337 · 2023: $8,072 · 2024: $1,755 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,477 · Travel and Lodging: $3,454 · Consulting Fee: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,476.75 |
| Travel and Lodging | $3,453.84 |
| Consulting Fee | $1,237.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $5,180.04 | 2023 | |
| Abbvie INC. | $3,815.97 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $702.50 | 2021-2024 | Entyvio |
| Gilead Sciences, INC. | $673.40 | 2021-2024 | Epclusa |
| E.R. Squibb & Sons, L.L.C. | $607.76 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $556.00 | 2023-2024 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $552.41 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $385.59 | 2023-2024 | Rebyota |
| Pfizer INC. | $313.24 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $312.81 | 2021-2023 | |
| Janssen Biotech, INC. | $246.39 | 2024-2025 | Tremfya, Stelara |
| Celgene Corporation | $158.72 | 2023 | Zeposia |
| Qol Medical, LLC | $128.05 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $126.50 | 2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $117.78 | 2024 | Tremfya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $113.93 | 2024 | Omnipod |
| Regeneron Healthcare Solutions, INC. | $109.64 | 2022 | |
| Merit Medical Systems INC | $104.26 | 2025 | Esophyx |
| Medtronic, INC. | $69.10 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Cramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.